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Abstract 
Background & Objective: The serum decoy receptor 3 (DcR3) level increases in chronic 
inflammatory diseases. The present study aimed to examine serum DcR3 and IL-6 levels in 
patients with stable and acute exacerbation of chronic obstructive pulmonary disease (COPD) 
and the correlation of this markers with airflow limitation. 
Methods: We measured serum DcR3 and IL-6 levels in 60 COPD patients (30 stable COPD 
(SCOPD), and 30 acute exacerbation of COPD (AECOPD)), and 30 control subjects and 
compared them with airflow limitation according to the COPD stage in the Global Initiative for 
Chronic Obstructive Pulmonary Disease (GOLD) criteria, peripheral O2 saturation (SpO2), and 
COPD Assessment Test (CAT) score. We also tested the association of serum DcR3 level with 
COPD patients’ clinical parameters. 
Results: Both serum DcR3 and IL-6 levels increased with increasing severity of airflow 
limitation in SCOPD and AECOPD groups (P < 0.01 to P < 0.001, respectively). It also 
increased in patients with AECOPD group compared with SCOPD group in GOLD stages III-IV 
(P < 0.05 to P < 0.001, respectively). In addition, there was a significant positive correlation 
between serum DcR3 level and IL-6, CAT score and Smoking history (per year). 
Conclusion: The study showed that serum DcR3 level increased with an increasing severity of 
airflow limitation in COPD patients, markedly in acute exacerbation phase. This increase was 
associated with a reduced quality of life and increased severity of hypoxia. These results suggest 
that DcR3 in COPD patients may be participate with its pathophysiology.  
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